Committed to Education


Maternity General: Administration of Rh (D) Immunoglobulin (Anti D) - WSLHD

Date Created V1.0 July 2004
Last Updated August 2013
Version Number 2.0
This Version Update 30 June 2020
Drug Commitee Approval 30 June 2020
NB: This document will not necessarily apply in all circumstances. It does not replace professional and/or clinical judgement. It may be amended/withdrawn at any time. Printed copies should not be relied upon. ALWAYS refer to the electronic copy. WSYD-GL203035.pdf • Release 1


Purpose and Scope

  • This document outlines the WSLHD RhD Immunoglobulin (Anti D) administration recommendations for Rh negative pregnant and postnatal women without pre-formed (immune) Rh D antibodies in order to prevent the development of Rh D Alloimmunisation.
  • The procedure covers Anti D administration advice for both routine prophylactic administration (28 / 34 weeks and postpartum) and non-routine administration necessitated by sensitizing events.
  • The dosing schedule is as per the tables over page
  • The procedure does not address the management of the Rh negative woman who already has pre-formed Anti D antibodies.

Intended Audience

  • This procedure applies to all medical and midwifery staff caring for pregnant Rh Negative women at Auburn, Blacktown and Westmead Hospitals.

Expected Outcomes

  • Staff will understand the reasons for and will comply with the appropriate recommendation and administration of Rd (D) Immunoglobulin to Rh (D) negative women without pre-formed Anti D antibodies.



You can download the full document here


Looking for General
Orientation information?

See more